Full-Time
Vice President
Real Assets Accounting, Financial Reporting
Posted on 9/6/2025
Blue Owl Capital
1,001-5,000 employees
Credit-focused alternative asset manager
Compensation Overview
$150k - $175k/yr
Chicago, IL, USA
In Person
This is a Chicago based position.
 Accounting (2) |
|---|
| , |
- 7+ years of real estate accounting experience. Candidates with exposure with real estate private equity, non-traded REITs or public REITs, with backgrounds as Big 4 auditors and/or relevant industry experience will be considered.
- Strong technical accounting skills with an emphasis on Historical Cost and Fair Value basis of accounting for real estate
- SEC reporting experience including Form 10-K, 10-Q, 8-K and other transactional offerings.
- Ability to understand leases, debt agreements, and private placement memorandums
- Must be deadline focused, organized, and exhibit problem-solving skills, able to handle multiple weekly, monthly and quarterly deadlines at the same time
- Ability to efficiently utilize excel spreadsheets and other accounting software.
- Oversee and accurately report financial data, month-end, quarter-end, and year-end accounting, valuation, and financial reporting in accordance with deadlines
- Prepare monthly net asset value and price per share in accordance with PPM documents
- Serve as the subject matter expert for financial reporting questions, including technical GAAP historical cost and fair value reporting accounting treatment
- Demonstrate strong understanding of real estate investment structures, mortgage documents, development agreements, partnership agreements, and purchase and sale agreements
- Determine the accounting and financial statement impacts due to significant transactions such as acquisitions, leases, and segment reporting to ensure accurate financial presentation
- Oversee third parties, monitoring their compliance with responsibilities, budgets, and deadlines
- Communicate effectively with CFO and CAO, providing regular and ad hoc communications, reporting, and analysis
- Coordinate and prepare financial statements and disclosures on Forms 10-Q, 10-K and 8-K with the SEC on a historical cost basis
- Coordinate with investment and asset management teams regarding property acquisitions/dispositions and ongoing property operations
- Manage audit deadlines
- Answer various questions from the audit and tax teams
- Coordinate the timely conclusion of audit reports
- Manage relationship with fund administrator and property managers
- Review the following prepared by the fund administrator: Incentive fee allocations and calculations, Management fee allocations and calculations, Acquisition entries ad hoc, Monthly NAV closes
- Work with investments team on ad hoc reports for current portfolio and acquisitions
- Implement effective internal controls, recommend to management the implementation of policies, procedures, processes, and controls based on continual analysis of current accounting processes.
- Bachelor’s degree in related field.
- CPA preferred, not required.
Blue Owl Capital operates as a leading alternative asset manager focused on credit markets. It offers credit-focused investment strategies managed by a team of investment professionals with diverse underwriting expertise across many industries. The product works by pooling investors’ capital into credit funds or customized accounts, where the investment team evaluates borrowers and structures, applies risk controls, and buys loans, bonds, and other credit instruments to build diversified portfolios that aim to generate returns. The company differentiates itself from competitors through a multi-perspective investment approach: each partner contributes a unique view on credit risk, creating a holistic assessment of opportunities and threats. Its goal is to deliver attractive risk-adjusted returns by actively managing credit portfolios across different market cycles.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
New York City, New York
Founded
2021
Simplify's Take
What believers are saying
- Big Tech's $700 billion AI spending in 2026 boosts data center financing growth by 6% in Q1.
- Sold half SpaceX stake at $1.25 trillion valuation, realizing 10x gains from 2021 investment.
- Raised $3 billion via private wealth channel in Q1 2026 despite minor evergreen outflows.
What critics are saying
- February 2026 withdrawal restrictions on Blue Owl Capital Corp II trigger $1.4 billion asset sales.
- Q1 2026 dividend cuts to $0.31 per share from $0.37 erode NAV to $14.41.
- Ares Capital undercuts pricing on middle-market loans, capturing Blue Owl's sponsor mandates.
What makes Blue Owl Capital unique
- Blue Owl Capital manages $315 billion AUM, specializing in direct lending to U.S. middle-market companies.
- Focuses on senior secured first lien loans and equity warrants, like SpaceX stake yielding 10x returns.
- Integrates credit with data center financing and triple net leases for AI infrastructure.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 51%Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential. * Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and existing investors, including Novo Holdings * Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026 * WIN378 has the potential to be the first-to-market ultra long-acting anti-TSLP antibody for asthma and COPD * WIN027 is a long-acting bispecific targeting TSLP and IL-13 with best-in-disease efficacy potential Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, and Sanofi Ventures. Proceeds will significantly extend the company's cash runway and enable multiple clinical readouts in the next 12 months. Since launching in January 2025, Windward Bio has in-licensed 2 clinical-stage assets, raised $365 million, and rapidly advanced both programmes[RW1] in the clinic. WIN378, the lead programme, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression of a wide array of immunological diseases. WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody with twice-yearly dosing. The financing will accelerate the development of WIN378, which is currently being studied in the Phase 2/3 POLARIS programme in asthma. The Phase 2 dose-ranging component of POLARIS is fully recruited, with initial data expected in the second half of 2026. The first Phase 3 study of WIN378 is expected to begin in the fourth quarter of 2026. The Phase 2 SIRIUS study in chronic obstructive pulmonary disease (COPD) is anticipated to start in the second quarter of 2026. WIN027, the second programme, is a highly potent, long-acting bispecific antibody targeting both TSLP and interleukin-13 (IL-13) - two well-validated and synergistic drivers of inflammation in severe asthma, COPD, and atopic dermatitis. WIN027 is currently in a Phase 1 study with data readout expected by the end of 2026. The financing will support multiple proof-of-concept studies across respiratory and dermatology indications starting in in the fourth quarter of 2026. "We are excited to expand our shareholder base of top-tier investors to include RA Capital, Janus Henderson, and Sanofi Ventures" said Luca Santarelli, MD, Founder, Chief Executive Officer, and Board Chair of Windward Bio. "This financing further strengthens our balance sheet and allows us to further advance our programmes of next-generation therapies for patients living with serious respiratory and dermatological diseases." Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, said: "Spearheaded by a highly experienced clinical and commercial leadership consisting of serial entrepreneurs, Windward Bio has made rapid progress since it launched in 2025, including bringing in a second clinical stage asset, WIN027. There is much more to be done towards improving dosing frequency and outcomes for the benefit of patients suffering from serious and chronic immunological conditions, and as a significant shareholder, we are pleased to support Windward Bio as it advances its innovative and developing pipeline into late-stage trials." About WIN378 WIN378 is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. WIN378 has been engineered to achieve half-life extension (HLE) and to have a silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 from Kelun Biotech (also known as SKB378) and Harbour BioMed (also known as HBM9378). WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. A Phase 2 study in COPD is anticipated to begin in the second quarter of 2026. About WIN027 WIN027 is a potential best-in-class, humanised bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, well-validated targets in immunological conditions. It has been engineered to achieve an extended half-life and enable less frequent dosing. Through this dual, long-acting inhibition, WIN027 is designed to set a new standard of efficacy in conditions such as asthma, COPD, and atopic dermatitis, potentially delivering deeper and more durable disease control than existing biologics. WIN027 is currently in Phase 1. Windward Bio licensed the global rights (excluding Greater China) for WIN027 from Qyuns Therapeutics (also known as QX027N). About Windward Bio Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead programme is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Media Enquiries Marie-Louise Jersin, Senior Communications Lead, [email protected]
Pacific Investment Management Co. has acquired the entire $400 million bond offering from Blue Owl Capital Inc., according to people familiar with the matter. The purchase represents a significant transaction in the business development company bond market, though further details about the terms and structure of the deal were not disclosed.
Blue Owl Capital Corp. has raised $400 million through a bond sale, marking the first such deal in over a month as private credit markets face heightened scrutiny. The investment-grade notes, maturing in 2028, were priced to yield 6.5%. The business development company, which provides direct loans to small and mid-sized firms, faces mounting concerns over exposure to companies threatened by artificial intelligence. Blue Owl's share price has fallen 43% this year, with OBDC trading at roughly 25% discount to net asset value. The bond sale priced at approximately 2.7 percentage points above similar-maturity Treasuries, reflecting widened spreads across the sector. Morgan Stanley arranged the sale, with proceeds earmarked for debt repayment. The deal may signal recovering investor confidence in private credit markets.
Vestwell, a financial technology company providing workplace savings solutions, has raised $385 million in Series E funding. The round was led by funds managed by Blue Owl Capital and Sixth Street Growth, with participation from new and existing investors. Part of the proceeds will support Vestwell's acquisition of Accrue 401k. The company offers a comprehensive suite of workplace savings products, including retirement plans, student loan repayment benefits and specialised accounts for education, emergencies and disability savings. Simpson Thacher represented Sixth Street Growth in the transaction. The legal team included Katherine Krause, Louis Argentieri and Christopher Haughey on mergers and acquisitions, Jennifer Albrecht on banking and credit, Erica Rozow on executive compensation, and David Blass and Meredith Abrams on asset management.
Gide advises Blue Owl Capital on the establishment of a joint venture with Covivio relating to three sites occupied by Thales. Deals & Disputes 7 April 2026 Its practices. Office. Gide advised Blue Owl Capital on the formation of a joint venture with Covivio relating to three real estate assets occupied by Thales in Vélizy-Meudon, at the heart of the Paris-Saclay innovation cluster. Following completion of the transaction on 1 April 2026, the joint venture holds the three assets constituting Thales' largest global site, representing more than 126,000 sq m and accommodating nearly 6,000 employees. These assets are now held 51% by Covivio and 49% by Blue Owl Capital. The transaction values the real estate campus at approximately €503 million. It forms part of Blue Owl Capital's strategy to invest in high-quality real estate assets, leased to blue-chip tenants and located in strategic markets. The Gide team advising Blue Owl Capital was led by partner Hugues Moreau and comprised counsels Sophie Gillard and Yannick Granjon, of counsel Véronique Queruel, Elisa Domingues and Axel Adolph on corporate and real estate matters, partner Benjamin Delaunay and Thomas Le Meur on regulatory aspects and the establishment of an OPPCI, as well as partner Pierre-Antoine Degrolard and Jonathan Navarro on foreign direct investment (FDI) matters.